We have developed substantial expertise in the field of infectious diseases and are committed to contributing to the eradication, elimination and control of certain infectious diseases.
Because life is a health journey, we work with international organizations (Gavi, the Vaccine Alliance, WHO and UNICEF) towards a world where vaccination could ensure that people no longer suffer from a preventable disease. We are committed to providing quality vaccines at affordable prices.
We are a longstanding partner of the Global Polio Eradication Initiative (GPEI) providing oral polio vaccines since 1999 and injectable polio vaccines since 2014 with the aim of eradicating the disease.
In 2016, we delivered 42 million doses of IPV standalone to UNICEF for GAVI countries.
Watch the video
Malaria is one of the most deadly infectious diseases in the world. According to the World Health Organization, there were approximately 219 million cases and 435,000 deaths due to malaria in 2017, mostly among African children. In Africa, one child dies of malaria every two minutes.
As a health journey partner, we supply our ASAQ Winthrop® drug, a fixed dose combination of artesunate-amodiaquine developed in partnership with the Drugs for Neglected Diseases initiative (DNDi), and for which we did not seek patent protection, at preferential prices. Since 2015, ASAQ Winthrop® is managed in partnership with Medicine of Malaria Venture (MMV) to maximize access for patients who need it most. Since its launch in 2007, ASAQ Winthrop® has enabled the treatment of over 450 million malaria attacks, including more than 43 million in 2016.
Sanofi also collaborates with national malaria control programs, ministries of Education and NGOs, and developed the Schoolchildren Against Malaria program, in order to promote prevention in schools in sub-Saharan Africa. In 2016, the program was still active in Gabon and Mozambique and close to 10,000 children and school staff benefited from awareness programs. In 2017-2018, additional awareness initiatives took place in Cameroon, Guinea and Togo.
Watch the educative cartoon
Sleeping sickness threatens millions of people in sub-Saharan Africa. This disease is fatal if not treated.
Because we are a health journey partner, thanks to our partnership with the WHO which started in 2001, over 40 million people have been screened for sleeping sickness and over 210,000 patients have been treated since then. Moreover, since 2009, we entered into an innovative partnership with the Drugs for Neglected Diseases initiative (DNDi) for the development of fexinidazole, an oral monotherapy for all stages of the disease. DNDi has carried out clinical testing and we are responsible for industrial development, production and regulatory submission. An oral monotherapy for sleeping sickness can contribute to simplifying treatment by avoiding systematic hospitalization and allowing patients to be treated closer to their homes.
Based on the positive results of the Phase II/III clinical trials completed in the Democratic Republic of Congo (DRC) and Central African Republic, fexinidazole received a positive scientific opinion from the European Medicines Agency (EMA) in November 2018, a decision that paves the way for the distribution of fexinidazole in endemic countries in 2019. On December 24th 2018, a Marketing Authorization has been granted in DRC in gambiense human African trypanosomiasis (HAT).
Fexinidazole represents a therapeutic breakthrough which will support sustainable elimination efforts as set out by the WHO’s roadmap for 2020.
Watch the video